A surprisingly long list of conditions can look like pancreatic cancer on scans, blood tests, and even during surgery. These range from inflammatory diseases and infections to benign anatomical quirks and tumors that originated somewhere else entirely. The overlap matters because pancreatic cancer carries one of the worst prognoses in oncology, and a misdiagnosis in either direction has serious consequences: an unnecessary major surgery for a benign condition, or delayed treatment for an actual malignancy. Understanding what can masquerade as pancreatic cancer is useful whether you are a patient facing an ambiguous scan result or simply trying to make sense of a complicated diagnostic process.
Autoimmune Pancreatitis
If one condition earns the title of pancreatic cancer’s most convincing impersonator, it is autoimmune pancreatitis. This rare inflammatory disease can mimic pancreatic cancer in its clinical presentation, imaging features, and laboratory results.1PubMed Central. Autoimmune pancreatitis misdiagnosed as a tumor of the head of the pancreas Both conditions show up as a mass in the pancreas, both cause obstructive jaundice (yellowing of the skin and eyes from a blocked bile duct), and both can produce elevated tumor markers in the blood.2Clinical Gastroenterology and Hepatology. Distinguishing Pancreatic Cancer From Autoimmune Pancreatitis: A Comparison of Two Strategies The resemblance is so strong that patients with autoimmune pancreatitis sometimes undergo a Whipple procedure, one of the most complex abdominal surgeries, before pathologists discover there was no cancer at all.
The most common form, IgG4-related autoimmune pancreatitis, involves elevated levels of a specific antibody and an inflammatory infiltration of the pancreas that creates a mass visible on imaging. The critical difference is that this condition responds well to steroid therapy, making accurate diagnosis before surgery especially important.3PubMed Central. IgG4-Related Autoimmune Pancreatitis Mimicking Pancreatic Cancer: A Report of Two Cases A multidisciplinary approach, combining imaging, serum IgG4 levels, and sometimes a trial of steroids, has become the standard recommendation for cases where autoimmune pancreatitis is suspected. But when the presentation is focal (a single mass in the pancreatic head rather than diffuse enlargement), even experienced clinicians can struggle to tell the two apart. Researchers have been developing CT-based computational tools to help distinguish focal autoimmune pancreatitis from pancreatic ductal adenocarcinoma before surgery, though these remain in early validation stages.4PubMed Central. A CT based radiomics nomogram for differentiation between focal-type autoimmune pancreatitis and pancreatic ductal adenocarcinoma
Other Forms of Pancreatitis
Autoimmune pancreatitis gets the most attention, but chronic pancreatitis of any type can form masses that raise alarm. Years of ongoing inflammation lead to scarring and fibrosis, and that fibrotic tissue can form a pseudotumor: a mass that looks and behaves like a tumor on imaging but is made of inflammatory and scar tissue rather than malignant cells. A classic imaging finding called the “double duct sign,” where both the pancreatic duct and the bile duct appear narrowed, was long considered a hallmark of pancreatic cancer. But in one study, roughly 15 percent of patients with that sign on imaging turned out not to have cancer at all; chronic pancreatitis accounted for several of those cases.5PubMed. The double duct sign in patients with malignant and benign pancreatic lesions
Groove pancreatitis is a particularly tricky variant. It affects the narrow space between the head of the pancreas, the duodenum, and the common bile duct. On imaging, it creates a mass in a location that is almost indistinguishable from a pancreatic head tumor. Differentiating groove pancreatitis from cancer based on imaging, symptoms, or lab work alone can be extraordinarily difficult, and the vast majority of these patients end up undergoing a Whipple procedure because malignancy cannot be ruled out with enough certainty.6PubMed Central. Groove pancreatitis: spectrum of imaging findings and radiology-pathology correlation Making things worse, groove pancreatitis can occasionally coexist with or even mask an actual cancer, so it must always be taken seriously in the differential diagnosis of a pancreatic mass.7Revista colombiana de GastroenterologÃa. Groove pancreatitis mimicking pancreatic cancer: Case report and literature review
Infections and Systemic Inflammatory Diseases
Diseases that produce granulomas, small clumps of inflammatory cells, can settle in the pancreas and form masses that look malignant. Tuberculosis is the classic example. Though pancreatic TB is rare, when it does occur it often presents as an isolated mass with abdominal pain and jaundice, mimicking a malignant pancreatic tumor both clinically and on imaging. The prognosis and treatment are completely different from cancer, making accurate diagnosis essential.8PubMed Central. Isolated Pancreatic Tuberculosis Mimicking Pancreatic Cancer: A Diagnostic Challenge
Sarcoidosis, an inflammatory disease that most commonly affects the lungs and lymph nodes, can occasionally debut as a pancreatic mass. In one reported case, a CT scan showed an apparent tumor in the pancreatic head along with enlarged retroperitoneal lymph nodes, leading to a preliminary diagnosis of metastatic pancreatic cancer. The actual diagnosis turned out to be systemic sarcoidosis, confirmed by granulomas on tissue biopsy, and the patient responded to steroid treatment.9PubMed Central. Mimicking pancreatic malignancy: a systemic sarcoidosis Even more challenging are cases of isolated pancreatic sarcoidosis, where no other organ shows signs of the disease. In those situations, the imaging appearance can be virtually indistinguishable from adenocarcinoma, and only tissue sampling reveals the benign truth.10PubMed Central. Isolated Pancreatic Sarcoidosis Masquerading as Pancreatic Adenocarcinoma: A Case Report
Tumors That Are Not Pancreatic Adenocarcinoma
Not every tumor in the pancreas is the dreaded ductal adenocarcinoma, which accounts for the vast majority of pancreatic cancer cases and carries the grim survival statistics people associate with the disease. Several other tumor types arise in the pancreas, and while some are malignant, they often have dramatically better outcomes. The problem is that on initial imaging, they can be hard to tell apart from adenocarcinoma.
Pancreatic neuroendocrine tumors are a notable example. These tumors arise from hormone-producing cells and tend to behave quite differently from adenocarcinoma: they grow more slowly, respond to different treatments, and carry a significantly better prognosis on average. Yet atypical neuroendocrine tumors can look remarkably similar to adenocarcinoma on MRI. In one study, five out of seven atypical neuroendocrine tumors were initially misread as adenocarcinoma on MRI reports.11PubMed Central. Differentiating pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinomas by the “Duct-Road Sign” A specific imaging feature called the “duct-road sign” showed promise in distinguishing the two, appearing in the vast majority of neuroendocrine tumors but none of the adenocarcinomas studied.
Solid pseudopapillary neoplasms are another category. These low-grade malignant tumors occur predominantly in young women and can arise anywhere in the pancreas, though they turn up slightly more often in the tail. They are generally treatable with surgery and carry a favorable prognosis compared to adenocarcinoma.12PubMed Central. Solid pseudopapillary neoplasm of the pancreas Because they present as solid masses in the pancreas, they can initially raise the same alarms as adenocarcinoma, particularly in patients outside the typical demographic.
Cancer That Came from Somewhere Else
A mass in the pancreas does not always mean the cancer started there. Metastatic disease to the pancreas accounts for only about two percent of pancreatic malignancies, but when it happens, the clinical presentation can closely mimic a primary pancreatic cancer.13International Journal of Surgery Case Reports. A rare case report of recurrent metastatic breast cancer mimicking primary pancreatic cancer Renal cell carcinoma is the most common primary cancer to send metastases to the pancreas, sometimes appearing years or even decades after the original kidney tumor was removed. Melanoma and lung cancer are also known culprits. In one reported case, metastatic breast cancer presented in the pancreas with symptoms and imaging findings that were virtually identical to a primary pancreatic malignancy.
This matters because the treatment for metastatic disease in the pancreas is usually quite different from the treatment for a primary pancreatic cancer. When someone has a history of a prior malignancy, that information should factor heavily into the diagnostic workup of any new pancreatic lesion, but this context can get lost, especially if the original cancer was treated long ago.
Masses Next Door to the Pancreas
The pancreas sits in a cramped neighborhood, nestled against the duodenum, the bile duct, major blood vessels, and the stomach. Masses that arise in neighboring structures can look like they originate in the pancreas, particularly on cross-sectional imaging.
Gastrointestinal stromal tumors of the duodenum are a well-documented example. Only a small fraction of these tumors arise in the duodenum, but when they do, the anatomical proximity to the pancreatic head can make them appear to be pancreatic masses on CT scans.14PubMed Central. A gastrointestinal stromal tumor of the duodenum masquerading as a pancreatic head tumor In some cases, these tumors have been mistaken for cystic pancreatic neoplasms when fistulas or internal fluid collections develop.15PubMed Central. A duodenal gastrointestinal stromal tumor with a large central area of fluid and gas due to fistulization into the duodenal lumen, mimicking a large duodenal diverticulum The complex shared anatomy of the duodenum and pancreatic head makes these misidentifications understandable, and they are sometimes only clarified during surgery.16International Surgery Journal. Uncommon presentation of duodenal gastrointestinal stromal tumor as large paraduodenal cyst: case report
Vascular anomalies represent another peripancreatic mimic. An intrapancreatic pseudoaneurysm, essentially a ballooning of a damaged blood vessel within the pancreas, can appear as a solid mass on imaging and be misdiagnosed as a pancreatic tumor.17PubMed Central. Pancreatic pseudoaneurysm mimicking pancreatic tumor: A case report and review of literature Mistaking a pseudoaneurysm for a tumor and attempting a biopsy could lead to life-threatening hemorrhage, making the distinction clinically urgent.
Anatomic Variants That Raise False Alarms
Sometimes the “lesion” on a scan is not a disease at all but a normal variation in how the pancreas developed. Focal fatty atrophy, where part of the pancreas has been replaced by fat tissue, can look like a mass on certain types of imaging. Annular pancreas, a congenital condition where pancreatic tissue encircles the duodenum, and ectopic pancreas, where small nests of pancreatic tissue grow in unusual locations, can also mimic focal lesions.18PubMed. Mimics of pancreatic neoplasms at cross-sectional imaging: Pearls for characterization and diagnostic work-up These variants are harmless and require no treatment. But if a radiologist is not specifically looking for them, they can trigger a cascade of unnecessary follow-up testing and anxiety. Familiarity with their typical imaging appearances is often enough to resolve the ambiguity.19PubMed Central. Mimics of pancreatic ductal adenocarcinoma
Why Tumor Markers Can Be Misleading
CA 19-9 is the most widely used blood marker in the workup of pancreatic cancer. But relying on it to distinguish cancer from non-cancer is risky, because the marker is not specific to malignancy. CA 19-9 can be elevated in a wide range of benign conditions, including bile duct stones, cholangitis (bile duct infection), pancreatitis, liver cysts, and liver abscesses.20International Journal of Surgery Case Reports. Dilemmas and limitations interpreting carbohydrate antigen 19-9 elevation after curative pancreatic surgery Anything that causes obstruction or inflammation in the biliary system can drive the number up.
One case report described a patient with choledocholithiasis (gallstones lodged in the bile duct) and obstructive jaundice whose CA 19-9 level was very high, a reading that would normally raise serious concern for cancer. The cause turned out to be entirely benign and resolved with removal of the stones.21PubMed Central. A Case of Choledocholithiasis and Obstructive Jaundice With a Very High Serum Carbohydrate Antigen 19-9 (CA 19-9) Level: A Case Report and Review of Literature A broader literature review found that non-cancerous conditions of the lungs, pancreas, liver, ovaries, kidneys, and other organs have all been associated with CA 19-9 levels above 1,000 U/mL, a threshold many clinicians would find alarming.22PubMed Central. Significantly Elevated CA 19-9 after COVID-19 Vaccination and Literature Review of Non-Cancerous Cases with CA 19-9 > 1000 U/mL The takeaway is that an elevated CA 19-9 level, even a dramatically high one, cannot confirm a cancer diagnosis on its own. It is a piece of the puzzle, not the answer.
The Limits of Tissue Sampling
When imaging and blood work are ambiguous, the next step is usually a tissue biopsy. The standard approach for pancreatic masses is endoscopic ultrasound-guided fine needle aspiration or biopsy, where a thin needle is passed through the stomach or duodenum into the pancreatic mass under real-time ultrasound guidance. This technique is the closest thing to a definitive diagnostic tool, but it is not perfect.
A meta-analysis covering 16 studies and over 800 patients found that fine needle core biopsy of solid pancreatic masses had a sensitivity of about 84 percent and a specificity of 98 percent.23Scientific Reports. Endoscopic ultrasound-guided fine needle core biopsy for the diagnosis of pancreatic malignant lesions: a systematic review and Meta-Analysis A single-center analysis of fine needle aspiration reported similar accuracy, around 80 percent for pancreatic lesions.24International Journal of Medical Sciences. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration: A single-center analysis Those numbers are good, but they mean that roughly one in five biopsies may not give a clear answer. The high specificity means that when the biopsy says cancer, it is almost always right. The weakness is on the other side: a negative or inconclusive biopsy does not reliably rule cancer out.
When initial results are inconclusive, repeat biopsies are performed. A study of repeat procedures found that certain factors increased the risk of a false-negative result, including mid-range lesion size, fewer needle passes during the procedure, and not using a specific type of cytology preparation.25PubMed Central. Risk factors and a prediction model for false-negative diagnosis in repeat EUS-FNA/B of pancreatic solid lesions following initially nondiagnostic or inconclusive findings This means that even after two rounds of biopsy, some patients are left without a definitive diagnosis and face a difficult decision about whether to proceed with surgery on the assumption of cancer or continue monitoring.
When Uncertainty Leads to Surgery
The inability to distinguish cancer from its mimics before surgery has real consequences. The Whipple procedure, the standard surgery for tumors in the head of the pancreas, is a major operation with meaningful risks, a significant recovery period, and long-term effects on digestion. When a patient undergoes this surgery and the pathology report comes back showing a benign condition, the surgery was technically unnecessary. Modified, less extensive pancreatic head resection approaches have been developed for situations where surgeons suspect a benign or borderline lesion, offering lower risk in appropriate candidates.26PubMed. Pancreatic head resection for noninflammatory benign lesions of the head of the pancreas
Yet the calculus is never simple. Pancreatic adenocarcinoma is aggressive enough that delaying surgery while pursuing additional testing carries its own risk. If there is a reasonable chance the mass is cancer and the biopsy is inconclusive, many surgeons and patients together decide that operating is the safer gamble. The clinical challenge is identifying which patients fall into the gray zone where additional workup, like a trial of steroid therapy for suspected autoimmune pancreatitis or specialized imaging sequences for possible neuroendocrine tumors, could spare them an unnecessary operation without jeopardizing their outcome if the mass does turn out to be malignant.
Why These Mimics Are So Hard to Catch
A common thread runs through nearly all of these look-alikes: the pancreas is a difficult organ to access and image clearly. It sits deep in the abdomen behind the stomach, surrounded by a tangle of ducts, vessels, and adjacent organs. Masses in or near the pancreas tend to present with a limited set of symptoms, primarily pain, jaundice, and weight loss, which overlap almost completely regardless of whether the underlying cause is cancer, inflammation, infection, or a congenital anomaly. The blood tests that rise in pancreatic cancer also rise in many benign conditions. And even biopsy, the gold standard for tissue diagnosis, misses the mark in a meaningful minority of cases because the needle may sample fibrotic or inflammatory tissue surrounding the tumor rather than the tumor cells themselves.
For patients navigating this uncertainty, the practical implication is that a second opinion from a center experienced in pancreatic disease is often worthwhile. Many of the conditions described here, particularly autoimmune pancreatitis, groove pancreatitis, and rare tumors, are uncommon enough that they may not be the first thing a generalist considers. Specialized pancreatic centers see these mimics more regularly and are more likely to include them in the differential before recommending surgery. When the diagnosis is unclear, asking whether the mass could be something other than adenocarcinoma is always a reasonable question.